Navigation Links
InCube Labs Enters into an Agreement with the Engineering Research Center for Revolutionizing Metallic Biomaterials
Date:10/23/2013

w technologies," said Dr. Harvey Borovetz, Distinguished Professor and Former Chair, Department of Bioengineering at Pitt. "Our relationship and agreement with InCube will help us harness scientific discoveries and translate them into commercial products that will ultimately improve healthcare."

"Through our strategic relationship with Pitt and its Coulter Translational Research Partnership program, we became engaged with the ERC-RMB. We have been very impressed with the team, the facilities and capabilities that Dr. Sankar has assembled, and we look forward to a long term relationship that accelerates the pace of innovation, and delivers more effective solutions to patients," said Mir Imran, Chairman and CEO, InCube Labs. "We are particularly excited about evaluating the biomaterials that the ERC-RMB is pioneering for commercial applications. We believe these innovations could lead to important clinical solutions that would dramatically improve patient outcomes."

As part of InCube Labs' efforts to commercialize innovative technologies, the company has a number of relationships with premier Universities around the country. These collaborations range from evaluating intellectual property for commercial viability to training and mentoring aspiring entrepreneurs and scientists.

About InCube Labs

Based in San Jose and San Antonio, InCube Labs is a life sciences research lab focused on developing medical breakthroughs that dramatically improve patient outcomes. InCube is led by Mir Imran, an accomplished medical innovator, entrepreneur and venture capitalist, who has founded more than 20 life sciences companies and holds more than 200 patents. Many of Imran's innovations have resulted in new standards of care, including the first FDA-appro
'/>"/>

SOURCE InCube Labs
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InCube Labs Launches Two New Life Sciences Companies in San Antonio
2. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
3. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
4. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
5. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
6. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
7. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
8. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
9. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
10. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
11. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 ABIVAX, a clinical ... vaccines, today announced that it has dosed in ... IIb/III clinical trial of ABX203 which is taking place in ... The study is designed to assess whether ABX203 can deliver ... (CHB) via controlling viral load for a much longer period ...
(Date:2/26/2015)... 2015   HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... million for the fourth quarter ended December 31, 2014, ... for the same period of 2013.  For the fiscal ... a 34% increase compared to revenue of $207.9 million ...
(Date:2/26/2015)... 26, 2015  Caris Life Sciences® today announced ... Genitourinary Cancers Symposium in Orlando, Fla. ... the Audio Poster Tour. Both studies utilized Caris ... service. These studies showed that panomic testing can ... carcinomas (RCC), providing insights that may drive selection ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 2Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 3Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 4Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 5
... DATA ), a technology and services company focused ... reported its,operating results for the first quarter of 2008., ... revenue decreased,approximately 41% to $2,088,000 and the Company reported ... both a basic and diluted basis. These,results compared with ...
... data support potential of asenapine in the treatment of ... schizophrenia and bipolar I ... ) today announced that an overview of asenapine clinical trials,from ... of the,American Psychiatric Association in Washington, D.C., May 3-8. Data ...
Cached Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7
(Date:2/26/2015)... Angeles, CA (PRWEB) February 26, 2015 ... Hair Restoration have monitored the evolution of one of ... The ARTAS system offers a machinery ... with accuracy from the patient’s scalp,” said Dr. Parsa ... FUE grafts automated, the speed at which the device ...
(Date:2/26/2015)... Imagine a day without access to clean, ... and there was no one to help. For more than ... In 2015, more than 2.5 billion people will also lack ... A new initiative led by Nevada’s Desert Research Institute ... specifically on women – who often bear the brunt of ...
(Date:2/26/2015)... Atlanta, GA (PRWEB) February 26, 2015 ... 2015 Movers & Makers Awards finalist. ... of exceptional companies involved in the manufacturing, processing, or distribution ... at the Gwinnett Center. This annual event serves as ... companies and is expected to draw more than 300 local ...
(Date:2/26/2015)... 26, 2015 Catalent Pharma ... delivery technologies and development solutions for drugs, ... announced several expanded capabilities within its European ... been implemented in response to increased customer ... proportion of highly-potent or temperature-sensitive investigational medical ...
(Date:2/26/2015)... A Beautiful Smile Dentistry is celebrating ... the following 50 year celebration specials to their patients. ... Sonic Care Diamond Clean or the Braun Oral B ... cost is $2895 for the Invisalign special (this is ... treatment procedures are priced accordingly). The practice is ...
Breaking Medicine News(10 mins):Health News:Newest Technology now Available at Parsa Mohebi Hair Restoration 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 3Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 3Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 2Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 3Health News:A Beautiful Smile Dentistry is Celebrating 50 Years in Practice! 2Health News:A Beautiful Smile Dentistry is Celebrating 50 Years in Practice! 3
... from United Kingdom have found a new antibiotic tigecycline ... Tetracycline known as Glycycline. // ,Due to indiscriminate ... antibiotic resistance shown by many organisms. Staphylococcus aureus is ... of concern as it causes most of the nosocomial ...
... Lipoma arborescens (tree like, diffuse articular lipomatosis) is a ... a very rare primary benign tumour of the synovium, ... slowly progressive chronically swollen knee. ,About 50 ... involving one knee, with occasional reports of involvement of ...
... bronze, die casting metal, alloys, rubber, and paints, ... of their unique properties, are being widely used ... medical diagnosis, sunscreens and cosmetics. Nano Zn powder ... hydrogen reaction, automobile tail gas disposal, environmental protection, ...
... from poor families who get fed in schools by the ... up for their iron and vitamin deficiencies//. ,The ... which have not found wide acceptance. Besides being more attractive ... proved more effective in improving iron deficiency-induced anaemia. The nutrition ...
... clinical trials of a novel drug called dnaJP1 for treatment ... been announced by Researchers at the University of California//. ... worldwide. It is thrice more common in women in men ... both sides of the body, such as the hands or ...
... 2005: India may have escaped from the Bird Flu epidemic ... is known that migratory birds are carrying the viral strain ... migrate to India in winter and were affected by the ... far the strain has killed 60 people due to the ...
Cached Medicine News:Health News:Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit 2Health News:Lipoma Arborescens: A Rare Tumor Of The Knee 2Health News:Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia 2Health News:Vitamin filled nutrition candy for School children 2Health News:Novel drug holds promise for treatment of Rheumatoid Arthritis 2
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... PalmScan P2000 Pachymeter [i.e., PalmScan P2000] ... operated biometer, which incorporates A-mode pulsed-echo ... to accurately measure the corneal thickness ... eyes. PalmScan P2000 includes two software ...
... PalmScan A2000 A-Scan [i.e., PalmScan A2000] device ... which incorporates A-mode pulsed-echo ultrasound,technology, and thus ... axial length (AL), anterior,chamber depth (ACD), and ... PalmScan A2000,device is also intended for calculating ...
... low TLR (<1%) and stroke rate - ... long-term durability., , , High Radial Strength: ... artery, increasing lumen diameter with chronic outward ... stent shortening, low profile design, Cordis TRUMARK™ ...
Medicine Products: